Key Highlights

  • The third-quarter 2026 net loss was USD 5.8 million, or USD 0.24 per share, compared with USD 7.5 million, or USD 0.37 per share, a year earlier, while nine-month net loss was USD 21.3 million.
  • Research and development expense rose to USD 6.5 million from USD 5.3 million on NDA-related work and commercial readiness, while general and administrative costs fell to USD 1.5 million from USD 1.8 million.
  • Cash, equivalents and short-term deposits were USD 15.5 million at September 30, 2026, before a USD 15 million milestone payment from Azurity for NDA acceptance that was received in early October.
  • The FDA goal date for the D-PLEX100 application under priority review is November 28, with a U.S. launch targeted for early 2027 by partner Azurity Pharmaceuticals, subject to approval.

Smaller Loss Ahead of the November 28 FDA Goal Date

PolyPid (NASDAQ:PYPD) held its third-quarter 2026 call on November 11, 2026. The company develops D-PLEX100, a therapy intended to prevent surgical site infection after colorectal surgery. Net loss narrowed to USD 5.8 million, or USD 0.24 per share, from USD 7.5 million, or USD 0.37, and the nine-month loss was USD 21.3 million, or USD 0.94 per share, versus USD 25.7 million, or USD 1.72. The CFO said general and administrative costs fell mainly because of lower non-cash charges on performance-based options, which vested after positive Phase III SHIELD II top-line results. Marketing and Business development spending was USD 0.4 million.

Azurity Deal, Reimbursement and European Rights Reverting

Management said the new drug application was accepted in July and labeling discussions are underway, but it would not discuss label content or inspection status before a decision. The Partnership with Azurity, signed in July 2026, has delivered USD 30 million so far, and a New Technology Add-on Payment application has been filed with CMS, with a decision expected in August 2027. If granted, it would give hospitals up to 75% of product cost above the standard payment. In Europe, a marketing application was submitted on September 14, a decision is expected in the second half of 2027 and a possible launch in 2028. The company also agreed with ADVANZ PHARMA to end the 2022 European agreement, so rights have returned to PolyPid.

Cash Into 2028, Pipeline Spending and What Management Did Not Say

Management said existing cash, plus expected Azurity proceeds and potential future proceeds, should fund operations into 2028. Adding the USD 15 million received in October to USD 15.5 million gives about USD 30.5 million (calculated, before any further spending). The company also plans modest spending over 18 months on PD01B, a candidate for diabetic foot infections, with a pre-IND meeting and first-in-human study planned for the second half of 2027. The call gave no Revenue guidance and no sales forecast. Hospitals add products to formulary account by account, so management said traction after any approval would build over several months, and approval itself is not assured.

Where Things Stand

Management says yes, but the claim rests on assumptions. PolyPid (NASDAQ:PYPD) said cash resources, together with expected Azurity proceeds and potential future proceeds, should last into 2028. Calculated cash after the October payment is about USD 30.5 million against a quarterly loss near USD 5.8 million. The outcome that matters most is the FDA decision by November 28, followed by an early 2027 launch, the August 2027 reimbursement decision and the second-half 2027 European decision.